source
- Celldex reports dual Phase 3 successes for barzolvolimab in refractory chronic spontaneous urticariaCelldex Therapeutics announced that its monoclonal antibody barzolvolimab achieved positive results in two Phase 3 studies of patients with treatment-refractory chronic spontaneous urticaria. The E…
- Otsuka and Ionis report ALS drug ulefnersen meets primary endpoint in phase 3 trialOtsuka and Ionis have completed the Fusion phase 3 trial of ulefnersen, an RNA‑targeted therapy for ALS patients with mutations in the FUS gene. The study enrolled 89 participants, with 73 forming…Fierce Biotech · 29d agoPositive readoutPositive